PARP1 and synucleinopathy: Direct and indirect inhibitors of aSyn aggregation, such as KYP-2047 [70,71], MCC950 [72], and MT101-5 [73], have also shown beneficial effects in rodent models of synucleinopathy, as have poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors like ABT-888 [74] and Veliparib [75].